USA — Janssen Biotech, Inc., an arm of Johnson & Johnson (J&J), has signed a strategic partnership and license deal with Evotec, a German drug maker to develop first-in-class targeted immune-based therapies for oncology.
According to a statement, the collaboration will hinge on Evotec’s integrated drug discovery and manufacturing capabilities.
During the pre-clinical R&D phase, the companies will collaborate closely — and then Janssen will take on full responsibility for both clinical development and commercialization.
In addition to the research funding, Evotec will receive an undisclosed upfront payment, success-based research, and commercial milestones of over US$350 million as well as tiered royalties on products from the partnership.
It is not Evotec’s first collaboration with Big Pharma; the company previously collaborated with Bristol Myers Squibb on a neurodegeneration candidate.
Bristol Myers exercised its option in 2021, paying Evotec US$20 million and accepting responsibility for any future development.
Meanwhile, Johnson & Johnson is confident it will meet its target of US$60 billion in pharmaceutical sales by 2025, citing continued growth in its cancer and immune disease drug portfolio, BioPharmadive reports.
The target, first set in late 2021, is 14% higher than the US$52.6 billion in drug sales reported by J&J on Tuesday. And achieving it will necessitate faster growth than the 1.7% increase in sales over 2021’s total.
Darzalex, a multiple myeloma treatment that has become a mainstay in treatment regimens for blood cancer, is sold by J&J.
It has recently received FDA approval for the cell therapy Carvykti and the bispecific antibody Tecvayli in multiple myeloma.
J&J released data in December for another bispecific antibody called talquetamab, which suggested it could be a promising option as well. J&J is researching talquetamab combinations with Tecvayli and Carvykti Duato stated.
Growth in J&J’s cancer drug portfolio will help offset weakness from the company’s COVID-19 vaccine, which has become a secondary option, and the loss of market exclusivity for the company’s rheumatoid arthritis drug Stelara, which is facing biosimilar competition.
While J&J anticipates steeper sales erosion for Stelara than it did for its inflammatory disease drug Remicade, it does not expect a significant drop this year, instead predicting flat-to-declining U.S. sales.
J&J is counting on its pharmaceutical division to deliver as it prepares to spin off its consumer division into a new standalone company called Kenvue, leaving a slimmed-down J&J that is more reliant on its drug unit.
In 2022, J&J’s consumer division, which sells well-known products such as Tylenol, earned US$14.9 billion in sales, while medical devices earned US$27.4 billion.
For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.
Be the first to leave a comment